“COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND”. Proceedings of the International Conference on Public Health, vol. 9, no. 1, Jan. 2025, pp. 45-67, https://doi.org/10.17501/24246735.2024.9105.